about
A randomized controlled trial to evaluate the efficacy of ultrasound-guided laser photocoagulation for treatment of benign thyroid nodules.Effects of an Intensive Lifestyle Intervention to Treat Overweight/Obese Children and AdolescentsMechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysisGlucagon: the effects of its excess and deficiency on insulin action.Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetesPortal vein glucose sensors do not play a major role in modulating physiological responses to insulin-induced hypoglycemia in humans.Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes.Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: A post hoc, pooled, patient-level analysis of 6 randomized controlled trials.Estimating plasma glucose from interstitial glucose: the issue of calibration algorithms in commercial continuous glucose monitoring devices.Plasma leptin and insulin relationships in obese and nonobese humans.Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in type 2 diabetes.GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials.Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning.Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study.Blood-to-brain glucose transport, cerebral glucose metabolism, and cerebral blood flow are not increased after hypoglycemia.Ghrelin is not necessary for adequate hormonal counterregulation of insulin-induced hypoglycemia.Rate of fall of blood glucose and physiological responses of counterregulatory hormones, clinical symptoms and cognitive function to hypoglycaemia in Type I diabetes mellitus in the postprandial state.Counterregulatory hormone and symptom responses to insulin-induced hypoglycemia in the postprandial state in humans.Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans.Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model.Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations.Different brain responses to hypoglycemia induced by equipotent doses of the long-acting insulin analog detemir and human regular insulin in humans.Blood-to-brain glucose transport and cerebral glucose metabolism are not reduced in poorly controlled type 1 diabetes.Validation of a counseling strategy to promote the adoption and the maintenance of physical activity by type 2 diabetic subjects.Intensive lifestyle intervention is particularly advantageous in poorly controlled type 2 diabetes.Different insulin concentrations in resuspended vs. unsuspended NPH insulin: Practical aspects of subcutaneous injection in patients with diabetes.Late post-prandial hypoglycaemia as the sole presenting feature of secreting pancreatic beta-cell adenoma in a subtotally gastrectomized patient.Impact of recent antecedent hypoglycemia on hypoglycemic cognitive dysfunction in nondiabetic humans.Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection.Long-term intensive therapy of IDDM patients with clinically overt autonomic neuropathy: effects on hypoglycemia awareness and counterregulation.Mechanisms of arterial hypotension after therapeutic dose of subcutaneous insulin in diabetic autonomic neuropathy.Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor TechnologyComparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A double-blind, randomized, crossover studyEffect of storage temperature of insulin on pharmacokinetics and pharmacodynamics of insulin mixtures injected subcutaneously in subjects with type 1 (insulin-dependent) diabetes mellitusMeticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDMLong-term intensive insulin therapy in IDDM: effects on HbA1c, risk for severe and mild hypoglycaemia, status of counterregulation and awareness of hypoglycaemiaUnawareness of hypoglycemiaPosttraumatic ileal stenosis mimicking Crohn's diseaseLong-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDMPost-hypoglycaemic hyperketonaemia does not contribute to brain metabolism during insulin-induced hypoglycaemia in humans
P50
Q33264063-8CCB7ECE-F2D2-4DD9-8984-6F4B6516E222Q33809863-52A0E2F2-D477-4C1B-8A2C-C4AB8C12F432Q33869737-4E4C9ECD-B845-489A-AA3B-6695D86F0805Q36418460-B630FCCB-3104-43DE-8457-F2876CA1248BQ36426750-6183273F-13FA-4A6D-96EC-E038C5222D4AQ37023046-9D05A4E2-A5AC-4E39-A2E3-7BFCBAEC3A95Q37331341-356A6391-A2CC-461E-9918-6F73C32DF155Q37626675-E3C5E671-86C3-421D-93A7-B0035C2C5CB2Q37967765-B95F9C25-DF50-4BE8-B104-54D3700859D6Q38358622-A68216E2-F46E-4763-BA67-56418EA5127BQ39987991-2EE7AD2A-9659-4501-9450-B70CC640F1C4Q40101119-89A4DA8C-549C-49D1-A771-6D8CF68BFB17Q41241979-E838E3BB-261A-4426-86EC-CD5F2390E4F8Q42756051-81E43570-DC32-481D-A941-8386FA471D30Q43687868-DBF348A8-2668-44EE-B86D-A8360B72C544Q44155469-2CBEB244-1F3A-490B-AD6F-14E9575DD4CEQ44362527-64EC8537-11B1-4107-AA7E-67795D7EF0BCQ44631824-4414DE20-7BEB-4D0E-96D8-B8EABCAFAFC5Q45995941-DA78EF6D-A168-4AE6-BE58-45E33194CDE9Q46783348-ACF7D45D-8139-44A9-BA83-4F59B98C73FFQ46824989-BCE43D9A-B32D-460D-93CF-E7B2F78058D6Q46847419-7406CA73-A67A-4FC0-828F-8F2750E700A3Q48401618-285615D1-6770-443E-BEF2-D2D02FDD29A8Q48607573-09BA08A3-D266-4705-89B9-1FC7BCAF2963Q50522263-DE76644E-D1F4-4B0D-9098-744166251724Q50592455-F62C3351-B935-4FFC-B2F8-CFE3BAD8D23BQ51577750-9550F3E2-8715-453D-9A50-40492E42F905Q52047085-EAC9A661-64EC-4CDD-9745-ADA66FA7878AQ53355436-3DF21F66-7350-4808-AB60-0B0429C2FBD3Q53916988-2969E186-CC16-4A34-B699-1A29E21AE760Q54235829-261EBDF8-1407-4BDA-996F-45D5F516C851Q57168592-6CB32487-BE15-42EC-8DD0-AF173D7DCE5FQ57951497-62EFAFB9-ECA1-47AB-B6D9-C7954C76CF83Q70252048-C2C64B4E-A019-46C6-8AB4-278E92535FE2Q70495234-D7BA8841-17AE-44DD-B70B-DB4E4EE4F445Q71469942-A07E98D4-DD34-458F-B0AD-83F236D21D59Q71567366-0AFC9048-A36E-46E1-9F3B-BD705007F186Q72037199-E0C19B26-E4C2-4AB6-8FA7-D5219B47BB59Q72643714-F8E2AF25-827C-4096-A6FC-56D1F3FE6743Q72679455-5192EF97-D3F1-44DA-9DF8-8935FC05B345
P50
description
researcher
@en
name
C Fanelli
@ast
C Fanelli
@en
C Fanelli
@nl
type
label
C Fanelli
@ast
C Fanelli
@en
C Fanelli
@nl
prefLabel
C Fanelli
@ast
C Fanelli
@en
C Fanelli
@nl
P106
P31
P496
0000-0003-4063-158X